Interferon alpha versus any other drug for chronic hepatitis D

Zaigham Abbas; Syed Salman Ali; Lubna Shazi

doi:10.1002/14651858.CD011727

Interferon alpha versus any other drug for chronic hepatitis D

Zaigham Abbas, Syed Salman Ali, Lubna Shazi

Research output: Contribution to journal › Article › peer-review

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the benefits and harms of interferon alpha as standard or pegylated plus other antivirals or other antivirals versus alpha as standard or as pegylated alone for people with chronic hepatitis D infection.

Original language	English
Article number	CD011727
Journal	Cochrane Database of Systematic Reviews
Volume	2015
Issue number	6
DOIs	https://doi.org/10.1002/14651858.CD011727
Publication status	Published - 2 Jun 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD011727

Cite this

@article{1c2ec1335c714ee2835837a5ecd45fd2,

title = "Interferon alpha versus any other drug for chronic hepatitis D",

abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the benefits and harms of interferon alpha as standard or pegylated plus other antivirals or other antivirals versus alpha as standard or as pegylated alone for people with chronic hepatitis D infection.",

author = "Zaigham Abbas and Ali, {Syed Salman} and Lubna Shazi",

note = "Publisher Copyright: {\textcopyright} 2015 The Cochrane Collaboration.",

year = "2015",

month = jun,

day = "2",

doi = "10.1002/14651858.CD011727",

language = "English",

volume = "2015",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Interferon alpha versus any other drug for chronic hepatitis D

AU - Abbas, Zaigham

AU - Ali, Syed Salman

AU - Shazi, Lubna

PY - 2015/6/2

Y1 - 2015/6/2

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the benefits and harms of interferon alpha as standard or pegylated plus other antivirals or other antivirals versus alpha as standard or as pegylated alone for people with chronic hepatitis D infection.

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the benefits and harms of interferon alpha as standard or pegylated plus other antivirals or other antivirals versus alpha as standard or as pegylated alone for people with chronic hepatitis D infection.

UR - http://www.scopus.com/inward/record.url?scp=85041832455&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD011727

DO - 10.1002/14651858.CD011727

M3 - Article

AN - SCOPUS:85041832455

SN - 1465-1858

VL - 2015

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 6

M1 - CD011727

ER -

Interferon alpha versus any other drug for chronic hepatitis D

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this